Skip to main content
CVM
NYSE Life Sciences

CEL-SCI's Multikine Wins Saudi NADR Designation; FDA Clinical Hold Still in Place

Arie Shkolnikov · Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
7
Price
$1.42
Mkt Cap
$25.856M
52W Low
$0.89
52W High
$7.8
52W Position info
60% above low
Off High info
82% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CVM sits 60% above its 52-week low of $0.89.

Summary

CEL-SCI said Multikine received Saudi SFDA NADR designation, with an MAA planned in 2-3 months and potential sales in 2027 or early 2028. The same filing confirms the FDA full clinical hold from September 17, 2026 remains in effect pending a CMC response due by December 10, 2026.


Key Events · Product Development and Regulatory · CVM

  • Saudi NADR Designation Granted

    The SFDA granted Multikine official designation under its New Accelerator Program for Drugs in Rare Diseases, with the application submitted by in-country partner Amarox.

  • MAA Filing Targeted Within 2-3 Months

    CEL-SCI and Amarox plan to submit a Marketing Authorization Application to the SFDA within the next 2-3 months, with a 160-working-day priority review target supporting potential launch and initial sales in 2027 or early 2028.

  • FDA Full Clinical Hold Unresolved

    The FDA's October 5, 2026 letter placed a full clinical hold communicated September 17, 2026, citing inadequate safety justification for a residual host-cell DNA specification change and insufficient product quality/comparability information after manufacturing renovations.

  • CMC Response Due by December 10, 2026

    CEL-SCI expects to submit the requested chemistry, manufacturing and controls information no later than December 10, 2026; the FDA's 30-day decision period begins only upon receipt of a complete response and does not assure the hold is lifted.


Analysis · CVM · Life Sciences

Saudi Arabia could become the first commercial market for Multikine, with an MAA planned within 2-3 months and a 160-working-day priority review that points to a 2027 or early 2028 launch. That is a real regulatory step forward for a company with no approved product. Against it, the filing confirms the FDA full clinical hold communicated September 17, 2026 is unresolved: CEL-SCI must answer CMC questions on residual host-cell DNA specification and post-renovation comparability, with the response expected no later than December 10, 2026, and the FDA's 30-day clock only starts once a complete response is received. The U.S. registration path stays blocked until then, so the Saudi pathway is carrying the commercial story.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CVM was trading at $1.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $25.9M. The 52-week trading range was $0.89 to $7.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CVM - Latest Insights